ARTICLE | Distillery Therapeutics
Neurology
August 1, 2018 8:10 PM UTC
Mouse studies suggest inhibiting MAPK could help treat autism. In a mouse model of autism, subcutaneous injection with a tool compound MAPK inhibitor decreased numbers of cortical progenitor cells and behavioral deficits and increased normal cortical cytoarchitecture and hippocampal and lateral septum volume compared with no treatment. Next steps could include testing other MAPK inhibitors in additional autism models.
Novartis AG has LTT462, a MAPK inhibitor, in Phase I testing for solid tumors...
BCIQ Company Profiles
BCIQ Target Profiles